Hong Kong Stock Movement | Lifetech Sci (01302) Rises Over 4% as G-iliacPro Iliac Artery Stent Graft System Receives Official NMPA Approval
Stock News
Jan 09
Lifetech Sci (01302) is currently up more than 4%. As of the time of writing, the stock has risen 4.43% to HK$1.65, with a turnover of HK$43.5211 million.
On the news front, Lifetech Sci announced that on January 7, 2026, its self-developed G-iliacPro Iliac Artery Stent Graft System received formal registration approval from the National Medical Products Administration (NMPA) of China.
The product is indicated for the endovascular treatment of abdominal aortic aneurysm combined with iliac artery aneurysm or isolated common iliac artery aneurysm. By reconstructing the internal iliac artery to ensure pelvic blood supply, it provides a more mature and comprehensive solution for clinical practice, representing a systematic upgrade to existing treatment options.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.